

## Special Issue

# Emerging Therapeutic Approaches to Esophageal Cancer

### Message from the Guest Editors

The incidence of esophageal cancer is continuously increasing and is one of the least studied and deadliest malignancies, worldwide. Due to a lack of early diagnosis, it often presents at an advanced stage. Currently, standard treatment for locally advanced esophageal cancer involves chemotherapy and/or radiation therapy prior to surgery. Despite this trimodality approach, survival remains very poor with a five-year survival rate of 20%. Thus, alternative therapeutic strategies that serve adjunctive roles to surgery are required to improve survival in esophageal cancer patients.

### Guest Editors

Dr. Pornima Phatak

1. Birmingham Veterans Affairs Health Care System, Birmingham, AL 35233, USA
2. Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA

Dr. James M. Donahue

1. Birmingham Veterans Affairs Health Care System, Birmingham, AL 35233, USA
2. Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA

Dr. Kaushal Asrani

Johns Hopkins School of Medicine, Baltimore, MD, USA

### Deadline for manuscript submissions

closed (30 August 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/132359](https://mdpi.com/si/132359)

*Cancers*

Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)